<DOC>
	<DOC>NCT00117078</DOC>
	<brief_summary>The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).</brief_summary>
	<brief_title>Aranesp® Monthly Preference Study - 2</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects must have signed written informed consent Be on Procrit® QW or Q2W for a minimum of 8 weeks Must currently be on a stable dose of Procrit® (defined as less than 25% change in Procrit® dose over the 4 week period immediately prior to enrollment, with no missed doses) Have Hgb 1012 g/dL for at least 4 weeks prior to study start Have 15 less than GFR less than 89 mL/min/1.73 m2 Currently receiving investigational erythropoietic agents Selfinjecting at home with Procrit® Expected to initiate renal replacement therapy (dialysis or transplantation) within 1 year of study start Have less than 1 year life expectancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Kidney disease, Renal, CKD (Chronic Kidney Disease)</keyword>
	<keyword>CRI (Chronic Renal Insufficiency), Pre-dialysis, Amgen</keyword>
	<keyword>Aranesp®, Darbepoetin alfa, QW dosing</keyword>
	<keyword>Q2W dosing, Q4W dosing</keyword>
	<keyword>Patient preference, Subject preference</keyword>
</DOC>